Back to top
more

Haemonetics (HAE)

(Delayed Data from NYSE)

$76.30 USD

76.30
451,069

+1.53 (2.05%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $76.35 +0.05 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 30% (173 out of 246)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Cardiovascular Systems Posts 2-Year LIBERTY 360 Study Data

by Zacks Equity Research

The 24-month outcome of LIBERTY 360 study by Cardiovascular Systems (CSII) demonstrates a constant relief from major amputation across all Rutherford Classifications (RC).

    Zacks Equity Research

    Haemonetics (HAE) Q1 Earnings & Revenues Beat Estimates

    by Zacks Equity Research

    Haemonetics' (HAE) year-over-year growth is backed by the solid execution of its multi-year turnaround strategy.

      Zacks Equity Research

      Zacks.com highlights: Lululemon Athletica, Sirius XM Holdings, Haemonetics, Lockheed Martin and ConocoPhillips

      by Zacks Equity Research

      Zacks.com highlights: Lululemon Athletica, Sirius XM Holdings, Haemonetics, Lockheed Martin and ConocoPhillips

        Tirthankar Chakraborty headshot

        Buy These 5 Efficient Stocks for Superb Returns

        by Tirthankar Chakraborty

        A company with a favorable efficiency level is expected to provide impressive returns as it is believed to be positively correlated with the stock's price performance.

          Zacks Equity Research

          Haemonetics Gains on Strong Plasma, Wider Global Footprint

          by Zacks Equity Research

          Strong growth of Haemonetics' (HAE) plasma-derived biopharmaceuticals is attributable to solid end-market demand.

            Zacks Equity Research

            Haemonetics' Plasma Momentum Solid, Margins Gain Traction

            by Zacks Equity Research

            Solid end-market demand for plasma-derived biopharmaceuticals continues to drive growth for Haemonetics (HAE).

              Zacks Equity Research

              Why is Haemonetics (HAE) Up 15.6% Since Its Last Earnings Report?

              by Zacks Equity Research

              Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                Zacks Equity Research

                Haemonetics (HAE) Q4 Earnings Meet, Revenues Beat Estimates

                by Zacks Equity Research

                Continued generation of new business and geographical expansion drive Haemonetics' (HAE) Q4 results.

                  Urmimala Biswas headshot

                  Medical Product Stocks May 8 Earnings List: HSIC, PEN & More

                  by Urmimala Biswas

                  An important component of the broader Medical sector, the Medical Product space consistently grabs attention owing to a string of upsides.

                    Zacks Equity Research

                    Haemonetics Rides High on Plasma, Blood Center Remains Weak

                    by Zacks Equity Research

                    We are optimistic about Haemonetics' (HAE) improved Plasma franchise as strong end-market demand for plasma-derived biopharmaceuticals consistently drives growth for the company.

                      Zacks Equity Research

                      SRDX or HAE: Which is a Better Medical Product Stock?

                      by Zacks Equity Research

                      Here we analyze the financials and fundamental factors of Haemonetics (HAE) and Surmodics (SRDX) to decide which is a better investment option.

                        Zacks Equity Research

                        Haemonetics' Plasma Tool Enhancement Gets 510(K) Clearance

                        by Zacks Equity Research

                        Haemonetics (HAE) witnesses steady growth in Plasma franchise, led by strong end-market demand for plasma-derived biopharmaceuticals.

                          Zacks Equity Research

                          Zacks.com highlights: Haemonetics, Alarm.com Holdings, Copart and inTEST

                          by Zacks Equity Research

                          Zacks.com highlights: Haemonetics, Alarm.com Holdings, Copart and inTEST

                            Tirthankar Chakraborty headshot

                            Buy These 4 Efficient Stocks for Impressive Returns

                            by Tirthankar Chakraborty

                            We have considered four popular ratios in order to find efficient companies that have the potential to provide impressive returns

                              Zacks Equity Research

                              Why Should You Add Haemonetics (HAE) to Your Portfolio Now?

                              by Zacks Equity Research

                              Market seems to be upbeat about Haemonetics' (HAE) newly-launched platform, NexSys Plasma Collection System (PCS).

                                Zacks Equity Research

                                Cerus (CERS) Looks Good: Stock Adds 9.5% in Session

                                by Zacks Equity Research

                                Shares of Cerus (CERS) rose 9.5% on Friday

                                  Zacks Equity Research

                                  Zacks.com highlights: Copart, Haemonetics, Surmodics, Alarm.com Holdings and ConocoPhillips

                                  by Zacks Equity Research

                                  Zacks.com highlights: Copart, Haemonetics, Surmodics, Alarm.com Holdings and ConocoPhillips

                                    Tirthankar Chakraborty headshot

                                    5 Top-Ranked Efficient Stocks to Boost Your Portfolio

                                    by Tirthankar Chakraborty

                                    A company with a favorable efficiency level will provide impressive returns irrespective of market conditions

                                      Zacks Equity Research

                                      Haemonetics (HAE) Up 4.2% Since Earnings Report: Can It Continue?

                                      by Zacks Equity Research

                                      Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                        Zacks Equity Research

                                        Haemonetics (HAE) Hits a 52-Week High: What's Driving It?

                                        by Zacks Equity Research

                                        Haemonetics (HAE) upbeat on integration of NexSys PCS device. A raised EPS guidance buoys optimism.

                                          Zacks Equity Research

                                          Medical Device Industry Outlook - February 2018

                                          by Zacks Equity Research

                                          Amid the concerns related to the tax reform, Congress' postponement of the medical device tax for another two years came as a huge relief to industry participants and investors.

                                            Zacks Equity Research

                                            Here's Why You Must Add Haemonetics (HAE) to Your Portfolio

                                            by Zacks Equity Research

                                            Haemonetics (HAE) delivers strong plasma revenues, driven by a robust performance in disposables and software in the United States. Also, the market seems upbeat about this new PCS platform.

                                              Zacks Equity Research

                                              Zacks.com featured highlights include: Lululemon, Haemonetics, NVR, YY and ConocoPhillips

                                              by Zacks Equity Research

                                              Zacks.com featured highlights include: Lululemon, Haemonetics, NVR, YY and ConocoPhillips

                                                Zacks Equity Research

                                                International Business Aids NuVasive, Pricing Woe Remains

                                                by Zacks Equity Research

                                                NuVasive (NUVA) plans to merge its U.S. Commercial and International sales functions into a global commercial organization. Also, several recent FDA approvals are encouraging.

                                                  Tirthankar Chakraborty headshot

                                                  5 Top Efficient Stocks to Add to Your Portfolio

                                                  by Tirthankar Chakraborty

                                                  Companies with favorable efficiency levels are likely to be on investors' radar irrespective of market conditions as price performance is believed to be positively correlated with efficiency